bioAffinity Technologies, Inc. announced on August 14, 2025, the closing of a private placement and warrant inducement transaction, generating approximately $1.2 million in aggregate gross proceeds. The private placement included the sale of 990 shares of Series B Convertible Preferred Stock and warrants to purchase approximately 6.7 million shares of common stock.
Concurrently, the warrant inducement transaction generated approximately $253,000 in gross cash proceeds from an existing accredited investor. This involved the exercise of outstanding August 2024 and October 2024 warrants, for which the exercise prices were reduced from $1.50 to $0.23 per share.
In consideration for the immediate exercise of these existing warrants, the investor received new unregistered warrants to purchase up to approximately 1.4 million shares of common stock at an exercise price of $0.352 per share. The net proceeds from these transactions are designated for working capital and general corporate purposes, providing crucial liquidity for the company's operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.